On Thursday, a Minnesota House committee approved a bill to create a task force to examine and advise on possible legalization of psychedelics such as ibogaine, MDMA, and psilocybin.
After adopting an amendment to strengthen its bipartisan appeal, lawmakers in the state continued to push for a measure to legalize cannabis.
It is possible to keep it in committee, so it can be included in a wider omnibus piece of health legislation.
Smith stated that there have been many studies in the medical community showing that these drugs can help with psychological disorders such as addiction, OCD, depression and seasonal depression. These medicines can help with a variety of problems, so I believe it’s time to legalize these drugs in Minnesota.
The bill would establish a Psychedelic Medical Task Force to advise the legislature on legal, medical and policy issues related to legalizing psychedelic medicines in the state.
The task force of 23 members would include officials and experts such as the governor, a designee and the state health commissioner. Two tribal representatives and people with expertise in substance abuse treatment, public policy experts, veterans with mental illnesses, and others.
The proposal, as it was introduced, stipulated that both the Senate majority leader and the House majority leader would each appoint two members to the task force. The committee approved an amendment Thursday that would allow the minority leaders from both chambers to each receive one of these appointments.
Smith, the sponsor of the amendment, stated in committee that the amendment was meant to make the bill more bipartisan.
The bill text states that members of the task force would have to “examine existing scientific studies on the therapeutic efficacy psychedelic medicines in the treatment of mental conditions, including depression and anxiety, as well as any other mental conditions or medical conditions for which it may be an effective treatment option.”
“Psychedelic medicine may include but is not limited to the use of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, LSD, bufotenine, DMT, 5-MeO-DMT, 2C-B, ibogaine, salvinorin A, and ketamine,” it continues.
The task force would have to assess whether any particular psychoactive is effective in treating any of these conditions. It would then compare its efficacy with conventional drug treatments. Finally, it would need to develop a plan to address the “statutory changes necessary to legalize psychedelic medicine.”
It states that the task force will submit two reports to the chair and ranking minorities members of the legislative panels with jurisdiction over human and health services. These reports will detail the taskforce’s findings regarding legalization of psychedelic medicines in the state. They also include the comprehensive plan under subdivision. The first report must be submitted no later than February 1, 2024 and the second by January 1, 2025.
Marijuana Moment tracks more than 1000 cannabis, psychedelics, and drug policy bills in the state legislatures and Congress this yea. Patreon supporters who pledge at least $25 per month get access to our interactive maps and charts, as well as a hearing calendar, so they don’t miss any developments.
Get access to our marijuana bill tracker by becoming a Patreon supporter.
—
“When one examines the results of recent studies on the topic, it becomes very difficult for one to disagree with that claim that psychedelics can be something like the microscope, telescope, or psychiatry,” Kurtis Hana, a registered lobbyist in Minnesota NORML, said to Marijuana Moment Thursday. Hanna is a citizen lobbyist who works pro bono to advance this bill.
He said, “A revolution is happening in the mental healthcare arena.” “It would be willful negligence on the Minnesota legislature not to pass this bill and start more thoughtful discussions about whether some kind of access program should exist for mental health patients Minnesota in the coming years.”
With the Democratic-Labor-Farmer party in the majority in the House and Senate, while holding the governorship, this session, there’s optimism about the prospects of advancing bold drug policy. This includes marijuana legalization legislation, which has been passed through many committees in both houses over the past weeks.
Minnesota is not the only state that has psychedelics reform in its sights.
Texas legislators have recently introduced a number of new bills that aim to promote and expand psychedelics research within the state.
The Oklahoma House of Representatives passed a bill to encourage research into the therapeutic potential of Psilocybin and provide legal protections against prosecution of people with qualifying conditions who have the psychedelic.
This month, a Rhode Island House Committee held a hearing about a bill that would eliminate penalties for possession and use of psilocybin. It would also allow home cultivation of psychedelic mushroom for personal use.
Washington State Senate passed a bill to establish a taskforce to support research into psilocybin, and to develop legal access to the psychedelic.
The three psychedelics research bill passed the Hawaii Senate and House earlier in the month.
Missouri lawmakers approved a GOP-led bill this month that would allow for research into the therapeutic value of certain psychedelics like ketamine, MDMA, and psilocybin.
These are just a few of the reforms being considered by legislators in this session.
Based on statistical modeling of policy trends, an analysis published last year in the American Medical Association journal concluded that most states will legalize psychotropic drugs by 2037.
Wisconsin Residents Spent Over $121 Million On Marijuana At Illinois Retailers In 2022, Legislative Analysis Finds
Photo elements courtesy carlosemmaskype, Apollo.
The post Minnesota Lawmakers Accept Bill To Create A Psychedelics Taskforce To Plan For Legalization originally appeared on Marijuana Moment.
